Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis

Rheumatology

Volumn 41, Issue 9, 2002, Pages 1052-1061

  Gottesdiener, K ^a   Schnitzer, T ^b   Fisher, C ^c   Bockow, B ^d   Markenson, J ^e   Ko, A ^a   DeTora, L ^a   Curtis, S ^a   Geissler, L ^a   Gertz, B J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Health Research of Hampton Roads   (United States)

^d Arthritis Northwest   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Efficacy; Etoricoxib; Osteoarthritis; Safety; Tolerability

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ADULT; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PLIABILITY; PYRIDINES; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME;

EID: 0036733531     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Preclinical biological profile of rofecoxib (Vioxx™, MK-0966): A potent, orally active and highly selective cox-2 inhibitor
2. Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract
3. Improving the adverse effect profile of NSAID therapy: A focus on selective COX-2 inhibitors
4. The discovery of rofecoxib [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
5. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
6. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
7. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS
8. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
9. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
10. MK-0663: A highly selective inhibitor of COX-2 in humans
11. Biochemical activity, safety and pharmacokinetics after multiple doses of MK-0663 (etoricoxib), a COX-2 specific inhibitor, in healthy volunteers
12. Testing the statistical certainty of a response to increasing doses of a drug
13. Probable inference, the law of succession, and statistical inference
14. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
15. Rofecoxib, a new cyclooxygenase 2 inhibitor shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis
16. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
17. Recommendations for the medical management of osteoarthritis of the hip and knee (American College of Rheumatology Subcommittee on Osteoarthritis guidelines)
18. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: Support for the concept of 'responders' and 'nonresponders'
19. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis
20. Guidelines for the management of rheumatoid arthritis